bioAffinity Technologies, Inc. is developing noninvasive diagnostics for early lung cancer detection leveraging flow cytometry combined with machine learning. Its flagship product, CyPath® Lung, is offered through a CAP-accredited and CLIA-certified lab subsidiary, supported by encouraging clinical sensitivity and specificity data. Recent progress includes enrollment in a pivotal clinical trial targeting high-risk patients with indeterminate pulmonary nodules. However, revenue growth remains modest, and the company continues to operate at a net loss with limited cash runway, necessitating further capital raises. Regulatory approvals beyond laboratory-developed test (LDT) status and broader commercialization represent critical next steps amid a competitive molecular diagnostics landscape.